SG&A Efficiency Analysis: Comparing TG Therapeutics, Inc. and MannKind Corporation

SG&A Efficiency: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, MannKind Corporation and TG Therapeutics, Inc. have shown contrasting trends in their SG&A efficiency.

MannKind Corporation

From 2014 to 2023, MannKind's SG&A expenses fluctuated, peaking in 2015 with a 38% increase from the previous year. Despite a dip in 2016, expenses rose again, reaching nearly 94 million by 2023. This reflects a strategic shift towards aggressive market expansion.

TG Therapeutics, Inc.

Conversely, TG Therapeutics displayed a more volatile pattern. After a low in 2016, their SG&A expenses surged by over 500% by 2021, indicating a significant investment in growth initiatives. However, by 2023, expenses stabilized, suggesting a more balanced approach.

These trends highlight the dynamic nature of SG&A management in the biotech sector, where strategic decisions can significantly impact financial outcomes.